Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
Contact us
Advanced
Homepage > Company > Media > Pharma News > 2015

Pharma News, 2015

Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials
- GBR 1302, a HER2xCD3 bi-specific antibody has successfully completed the preclinical evaluation phase- Preclinically, GBR 1302 has demonstrated superiority over current antibody therapies against mo...
Raptor stops developing RP103 drug after it fails to treat nonalcoholic steatohepatitis in children
Raptor stops developing RP103 drug after it fails to treat nonalcoholic steatohepatitis in children
Raptor Pharmaceutical said that its RP103 (cysteamine bitartrate) drug failed to meet the main goal in a second mid-stage study.
Roche ‘Very Unlikely’ to Pursue a Midsize Acquisition Soon
Roche ‘Very Unlikely’ to Pursue a Midsize Acquisition Soon
LONDON— Roche Holding AG is unlikely to pursue midsize acquisitions soon because companies with drugs in late-stage development are too expensive, Chief Executive Severin Schwan said in an interview...
FDA grants Fast Track status for MediciNova's MN-001 to treat idiopathic pulmonary fibrosis
FDA grants Fast Track status for MediciNova's MN-001 to treat idiopathic pulmonary fibrosis
MediciNova, Inc.
La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
La Jolla Pharmaceutical Company (Nasdaq.
AbbVie : FDA Okays HUMIRA To Treat Moderate To Severe Hidradenitis Suppurativa
AbbVie : FDA Okays HUMIRA To Treat Moderate To Severe Hidradenitis Suppurativa
AbbVie (ABBV) announced that the U.
Lasker prizes recognize Ebola response, DNA damage, and cancer research
Lasker prizes recognize Ebola response, DNA damage, and cancer research
Start placing your Nobel Prize bets.
AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial
AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial
AcelRx Pharmaceuticals, Inc.
Implant 'traps' spreading cancer cells
Implant 'traps' spreading cancer cells
A small sponge-like implant that can mop up cancer cells as they move through the body has been developed by US researchers.
FDA Approves Durlaza
FDA Approves Durlaza
New Haven Pharmaceuticals, Inc.
New cholesterol-lowering drugs are discussed by UB cardiologist and researcher
New cholesterol-lowering drugs are discussed by UB cardiologist and researcher
The new statin alternatives, the class of drugs known as PCSK9 inhibitors, which are just coming onto the market, are a welcome addition for treating high cholesterol, said Stanley F.
FDA Grants Genentech's Alectinib Priority Review For ALK-Positive Lung Cancer
FDA Grants Genentech's Alectinib Priority Review For ALK-Positive Lung Cancer
Genentech, a member of the Roche Group (RHHBY), announced that the U.
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds